Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues.


Humanization of murine monoclonal antibodies for human therapy has commonly been achieved by complementarity-determining region (CDR) grafting, in which murine CDR loops are grafted onto human framework regions. Difficulties with that method have revealed the importance of certain framework residues in determining both the 3-D structure of CDR loops and the… (More)